Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Kirk © who wrote (9475)	4/26/2020 2:45:54 PM
From: Brian Sullivan	1 Recommendation Recommended By Winfastorlose Read Replies (1) \| Respond to of 26439

one or more of the studies using Hydroxycholoquine was terminated because too many who got the drug died or had significant side effects such as heart arrhythmia That was a Brazilian test where they were given triple the normal dosage thedailybeast.com

To: Kirk © who wrote (9475)	4/26/2020 2:54:04 PM
From: Brian Sullivan	2 Recommendations Recommended By Investor2 Kirk © Respond to of 26439

This must be given early before intubation, if you wait until someone is intubated then the results are not much different than not giving the treatment.

To: Kirk © who wrote (9475)	4/26/2020 3:14:33 PM
From: Investor2	1 Recommendation Recommended By Winfastorlose Read Replies (1) \| Respond to of 26439

Per the World Health Organization study published in 2017, before Trump came out in support of hydroxychloroquine and everyone who hates Trump now hates HCQ, - "Apart from halofantrine, the oral antimalarial drugs, particularly chloroquine and piperaquine, have been used extensively with very few reports of cardiotoxicity." - "Despite hundreds of millions of doses administered in the treatment of malaria, there have been no reports of sudden unexplained death associated with quinine, chloroquine or amodiaquine, although each drug causes QT/QTc interval prolongation." I copied the above quotes directly from the 2017 WHO report. who.int Best wishes, I2